keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NecroX-7 (LC-280126) 是一种有效的自由基清除剂和 HMGB1(高迁移率族蛋白 1) 抑制剂。NecroX-7 可以作为对乙酰氨基酚毒性的解毒剂。NecroX-7 通过抑制缺血/再灌注损伤中 HMGB1 的释放发挥保护作用。NecroX-7 抑制 HMGB1 诱导的 TNF 和 IL-6的释放,以及TLR-4和晚期糖基化终产物受体的表达,用于移植物抗宿主病 (GVHD) 研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 497 | 现货 | ||
5 mg | ¥ 1,230 | 现货 | ||
10 mg | ¥ 1,980 | 现货 | ||
25 mg | ¥ 4,570 | 现货 | ||
50 mg | ¥ 7,870 | 现货 |
产品描述 | NecroX-7 (LC-280126) is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. Additionally, NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 may be use for treatment of graft-versus-host disease (GVHD) research [1]. |
体外活性 | NecroX-7 (0-40 μM, 3-4 d) inhibits activated or proliferating T cells without causing apoptosis [1]. NecroX-7 (0-40 μM) significantly lowers HMGB1 levels in a dose-dependent manner [1]. NecroX-7 inhibits formation of mitochondria-specific ROS/reactive nitrogen species in H9C2 cells and hepatocytes after induction by tert-butyl hydroperoxide or doxorubicin [1]. NecroX-7 increased regulatory T cell numbers, which may be associated with regulation of differentiation signals independent of HMGB1 [1]. Cell Proliferation Assay [1] Cell Line: CD4 T cells Concentration: 0, 0.625, 1.25, 2.5, 5, 10, 20, and 40 μM Incubation Time: 3-4 d Result: Showed a marked reduction in splenocyte proliferation, in a dose-dependent manner. Modulated alloreactive T cell responses. |
体内活性 | NecroX-7 (0-0.3 mg/kg, IV, once injection at 2-d intervals, for 2 weeks) markedly reduces GVHD-related mortality and inhibits severe tissue damage [1]. NecroX-7 protects mice against lethal GVHD by reciprocal regulation of regulatory T/Th1 cells, attenuating systemic HMGB1 accumulation and inhibiting HMGB1-mediated inflammatory response [1]. Animal Model: Female BALB/c and C57BL/6 mice (Eight-week-old, with GVHD) [1] Dosage: 0.03, 0.1, and 0.3 mg/kg Administration: IV, once injection at 2-d intervals, for 2 weeks Result: Observed statistically significant prolonged survival at doses ≥0.1 mg/kg: 30–60% of mice in these treatment groups survived for >50 d. Significantly improved clinical signs and prolonged survival, and the mice showed a reduction in clinical manifestations of acute GVHD, including weight loss, hunched posture, diarrhea, and ruffled fur. |
别名 | LC-280126, LC28-0126, LC28 0126 |
分子量 | 439.57 |
分子式 | C24H29N3O3S |
CAS No. | 1120332-55-9 |
keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NecroX-7 1120332-55-9 Immunology/Inflammation NADPH-oxidase LC 280126 NecroX7 LC-280126 NecroX 7 LC28-0126 LC280126 LC28 0126 Inhibitor inhibitor inhibit